Drug Database
DT

DTP-HBV-Hib vaccine (Comvac5)

✓ Approved

Bharat Biotech Ltd. · Vaccine · Vaccine

What is DTP-HBV-Hib vaccine?

DTP-HBV-Hib vaccine is a vaccine developed by Bharat Biotech Ltd.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesComvac5
CompanyBharat Biotech Ltd.
Drug ClassVaccine
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

DTP-HBV-Hib vaccine is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedBMJ public health2026-07-17

Prevalence of zero-dose vaccination and its associated factors in urban areas of Somali region, Ethiopia: a mixed-methods approach.

Elmi Abdifatah A, Ibrahim Mahamed M, Farah Abdi A, Tahir Ahmed A et al.

Despite global progress in immunisation, vaccine coverage remains uneven in many low- and middle-income countries. Urbanisation has widened disparities, particularly among children in informal settlements. Ethiopia has a high zero-dose burden, with the Somali region identified as a hotspot. However, urban areas in this region remain understudied. This study assesses the prevalence of zero-dose children and associated factors in urban areas of the Somali region to inform targeted interventions. Using a mixed-methods approach, data were collected from 842 households in three urban towns through community surveys and six key informant interviews. The primary outcome was the proportion of zero-dose children, defined as those who had not received the first dose of the DTP-containing vaccine (Penta-1) during their first year of life, based on vaccination card records or caregiver recall. This included children who had never received any vaccine or had received some vaccines but not Penta-1. Quantitative data were analysed using logistic regression, while qualitative findings were examined thematically using the GAVI IRMMA framework. Strict quality control measures ensured the reliability of results. Of 842 targeted households, 827 participated (98.2% response). Findings reveal that 30% of children surveyed were identified as zero-dose for vaccination. Children were significantly more likely to be zero-dose if their mothers had no antenatal care (adjusted OR, AOR ~5.0), required permission for vaccination (AOR ~3.4), delivered at home (AOR ~3.1), or did not receive the second dose of tetanus toxoid (AOR ~2.7). In contrast, higher perceived household wealth and at least one postnatal care visit reduced the likelihood of zero-dose by about 45% and 55%, respectively. Zero-dose children were concentrated in urban peripheries and informal settlements with limited healthcare access, poor identification strategies and reliance on facility-based vaccination services. The study highlights a higher prevalence of zero-dose children in urban areas, underscoring the urgent need for improved identification and mapping in underserved communities. Strengthening advocacy, diversifying immunisation approaches and addressing systemic barriers are essential to improving vaccine access and reducing the zero-dose burden.

PubMedJournal of bioenergetics and biomembranes2026-07-17

AURKA regulates HBV-induced hepatic stellate cell inflammation and liver fibrosis by modulating K48-linked ubiquitination and proteasomal degradation of TLR3.

Wu Hongjie H, Wang Tianbao T, Yang Fang F, Yue Mingqiang M et al.

Chronic hepatitis B (CHB), caused by persistent hepatitis B virus (HBV) infection, continues to pose a major global health threat. Aurora kinase A (AURKA) has been implicated in fibrosis, yet its role in HBV-induced liver fibrosis remains unclear. This study investigated the function and mechanism of AURKA in hepatic stellate cell (HSC) activation and fibrogenesis during CHB. Bioinformatics screening of GSE83148 dataset and validation in human CHB liver specimens, LX-2 HSCs treated with conditioned medium (CM) from HBV-replicating cells, and a persistent HBV recombinant cccDNA (rcccDNA) mouse model established by tail-vein injection of Ad/rcccDNA were performed. Gene and protein expression was analyzed by quantitative PCR and immunoblotting, respectively. Cytokine levels were measured by ELISA. Mitochondrial function was assessed via ROS and JC-1 assays. Protein interactions and ubiquitination were evaluated by co-immunoprecipitation (Co-IP) and protein stability assays. In additional experiments, LX-2 cells were stimulated with purified HBV virions at varying MOIs to assess direct viral effects. AURKA was significantly upregulated in CHB patients and HBV-CM-treated LX-2 HSCs. In LX-2 HSCs, AURKA knockdown attenuated HBV-CM-induced inflammatory cytokine secretion (IL‑1β, IL‑6), mitochondrial dysfunction (mitochondrial ROS, mitochondrial membrane potential), HSC proliferation, and fibrotic marker expression (COL I, α-SMA). Mechanistically, AURKA interacted with TLR3 and was associated with its K48-linked polyubiquitination and degradation. TLR3 silencing abolished the protective effects of AURKA knockdown. In vivo, using a persistent HBV rcccDNA mouse model, AURKA knockdown ameliorated HBV-induced hepatic inflammation and fibrosis by upregulating TLR3. Notably, purified HBV virions alone were sufficient to dose-dependently induce AURKA expression and downstream fibrotic responses in HSCs. This study identifies a novel AURKA/TLR3 axis that regulates HBV-induced HSC activation and liver fibrosis, positioning AURKA as a potential therapeutic target for CHB-associated fibrosis.

PubMedJournal of viral hepatitis2026-07-17

Trends in Hepatitis B, Hepatitis C, and HIV Seroprevalence in the Netherlands: Insights From Two Decades of Nationwide PIENTER Serosurveys.

van Straten Christine G J I CGJI, van Benthem Birgit H B BHB, van der Klis Fiona R M FRM, Smits Gaby G et al.

Hepatitis B (HBV), hepatitis C (HCV), and HIV remain public health challenges despite effective treatments and preventive options. Infections are often asymptomatic, leading to undiagnosed cases, onward transmission, and preventable morbidity and mortality. In the Netherlands, disease burden is concentrated in specific populations, with many undetected infections. We estimated HBV, HCV, and HIV seroprevalence, identified determinants, and assessed trends over 20 years using data from 14,444 participants aged 15-79 years from three nationwide cross-sectional serosurveys (PIENTER: 1995-1996, 2006-2007, and 2016-2017). Participants completed questionnaires on demographics, behaviour, and socio-economic factors, and serum samples were tested for HBV and HCV in all rounds and HIV in 2017. Seroprevalence estimates were weighted to the Dutch population, trends were analysed using weighted Poisson regression, and determinants were evaluated using multivariable Poisson regression. Weighted HBV seroprevalence remained stable across surveys (3%-5% past or present infection; < 0.4% active infection). HBV prevalence was highest among first-generation migrants, with older age, migration background, and STI history as key determinants. HCV seroprevalence remained low (< 0.4%) and was highest among non-Western migrants. HIV prevalence was 0.1% and highest among non-Western migrants and men who have sex with men. Only 9% of active HBV cases were aware of their status. Overall, HBV, HCV, and HIV seroprevalence remain low in the Netherlands but are concentrated in specific groups with limited awareness. These findings support targeted prevention, screening, and linkage-to-care strategies to achieve the 2030 WHO elimination goals and highlight the importance of continued population-based (sero-)monitoring to guide public health policy.

PubMedVirology journal2026-07-17

NGS-diagnosed HBV encephalitis with isolated left parietal lobe involvement: a case report.

Zhou Zihan Z, Zhou Zhangning Z, Zhang Longqi L

Viral encephalitis refers to the inflammation of the brain parenchyma caused by viral infection, usually manifested as fever, unconsciousness, seizures, and meningeal irritation symptoms. The non-specific clinical manifestations, combined with incomplete medical history, often lead to missed diagnoses and inappropriate treatments. We present a case of Hepatitis B virus (HBV) encephalitis, manifesting as isolated left parietal lobe involvement. The patient is a chronic hepatitis B virus carrier who did not receive antiviral therapy. Upon onset, the main symptoms were unconsciousness, fever, and seizures. He was diagnosed with HBV encephalitis thru next-generation sequencing (NGS) testing of the cerebrospinal fluid (CSF). After antiviral treatment with entecavir and general symptomatic treatment, the patient's clinical symptoms disappeared, and a follow-up brain MRI showed that the lesion had almost completely resolved. Central nervous system (CNS) infections caused by HBV are incredibly uncommon in clinical practice. This case highlights that the clinical manifestations of HBV encephalitis are nonspecific and prone to being missed, while neuroimaging often reveals an isolated lesion. Early application of NGS for accurate pathogen diagnosis is crucial to reduce misdiagnosis.

PubMedFrontiers in nutrition2026-07-17

Factors influencing breastfeeding failure in mothers with hepatitis B infection: a qualitative study.

Jiang Xin X, Jiang Hui H, Huang Rong R

To explore the factors contributing to breastfeeding failure among mothers infected with the hepatitis B virus (HBV) from the perspectives of stress and decision-making, with a specific focus on psychological factors. A qualitative, descriptive design using semi-structured interviews. Purposive sampling recruited 21 HBV-positive mothers at Shanghai First Maternity and Infant Hospital between February 1 and May 10, 2023. Data collection continued until thematic saturation. Interviews were audio-recorded, transcribed verbatim, and analyzed via thematic analysis with NVivo 12.6.1 software. Measures to ensure data trustworthiness included member checking, peer debriefing, and investigator triangulation. Three participants withdrew before completion, resulting in 18 final interviews. Mean maternal age was 32.28 ± 4.80 years; 56% delivered by cesarean section, 67% had female infants. Five mothers were HBsAg-positive only, 13 were both HBsAg- and HBeAg-positive. Four mothers used partial breastfeeding, 13 formula feeding, only one practiced exclusive breastfeeding during hospitalization. Four core themes emerged: "Inadequate Knowledge of HBV Transmission Routes, Breastfeeding Benefits, and Resultant Decision-Making Uncertainty" (Cognitive Knowledge Deficits); Persistent Fear of Getting An Infant Infected With HBV, Despite Reassurance and Medical Information From Healthcare Providers (Emotional/psychological concerns); Practical Technical Difficulties in Breastfeeding, and Lactation-related Complications Compromising Feeding Sustainability (Persistent physiological and technical breastfeeding barriers); Family Members' Opposition to Breastfeeding that Increases Above the Maternal Feeding Intent and Directly Affects Infant Feeding Outcome (Family opposition and maternal intent deviate from infant feeding outcomes). Breastfeeding among HBV-positive mothers is influenced by multiple factors including knowledge gaps, psychological concerns, physical challenges, and social pressures. Interventions should focus on improving knowledge, reducing psychological stress, enhancing technical support and engaging family members to promote breastfeeding continuation. The study identifies HBV-positive mothers' breastfeeding barriers. It offers evidence for healthcare institutions' targeted strategies and helps improve breastfeeding rates and infant health.

PubMedAIDS research and therapy2026-07-17

B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase.

Avihingsanon Anchalee A, Leong Chee Loon CL, Hung Chien-Ching CC, Kiertiburanakul Sasisopin S et al.

Data on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with both HIV-1 and HBV are limited, particularly for treatment-experienced people. ALLIANCE was a randomized, double-blind, active-controlled, phase 3 study of B/F/TAF versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve adults with HIV-1 RNA ≥ 500 copies/mL and HBV DNA ≥ 2000 IU/mL. Participants received continuous B/F/TAF through 144 weeks (≥ 96 weeks of blinded treatment plus 48-week optional open-label extension [OLE]) or switched to B/F/TAF after ≥ 96 weeks of DTG + F/TDF through 48 weeks of OLE. Here we report outcomes from the OLE. 121 participants were included in the continuous B/F/TAF group; 89 in the switch group. Median B/F/TAF exposure was 186.4 and 48 weeks, respectively. HIV-1 and HBV suppression rates (missing = excluded) were maintained in both groups (B/F/TAF Week 144: 99.0% and 80.2%; switch OLE Week 48: 95.4% and 86.6%, respectively). Both groups had improved alanine aminotransferase normalization. HBV envelope antigen loss and seroconversion occurred in 44.8% and 29.3%, respectively, of participants receiving continuous B/F/TAF (Week 144) and 17.0% and 12.8% in the switch group (OLE Week 48). HBV surface antigen loss and seroconversion occurred in 22.5% and 15.5% (continuous B/F/TAF), and 4.3% and 0% (switch group) of participants, respectively. One participant (continuous B/F/TAF) discontinued due to study drug-unrelated treatment-emergent adverse event. No treatment-emergent resistance was reported. B/F/TAF was effective in HIV-1 and HBV suppression and well tolerated in treatment-naïve individuals for ≤ 3 years and ≤ 1 year after switching from a TDF-based regimen. Trial registration ClinicalTrials.gov NCT03547908 (first registration 2018-05-24).

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about DTP-HBV-Hib vaccine